Merocarb (Meropenem Anhydrous)

Merocarb is a carbapenem antibiotic used to treat serious bacterial infections in hospitalized patients.

• Complicated intra‑abdominal infections: effective bacterial eradication in patients with severe intra‑abdominal infection.
• Complicated urinary tract infections: rapid clearance of resistant uropathogens in complicated UTIs.
• Hospital‑acquired pneumonia: broad‑spectrum coverage for Gram‑negative and Gram‑positive pathogens in nosocomial pneumonia.
• Ventilator‑associated pneumonia: targeted therapy for ventilated patients with pneumonia caused by resistant organisms.
• Severe sepsis and septic shock: critical antimicrobial support to control systemic infection and improve outcomes.

• Meropenem exerts its antibacterial activity by binding to penicillin‑binding proteins (PBPs) located on the bacterial cell wall. This binding inhibits the final transpeptidation step of peptidoglycan synthesis, weakening the cell wall and leading to osmotic instability, cell lysis, and bacterial death. It is active against Enterobacteriaceae, Pseudomonas aeruginosa and many other resistant pathogens.

Merocarb may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild gastrointestinal upset that may resolve without intervention.
• Diarrhea: loose stools occurring during therapy, usually self‑limiting.
• Headache: transient cranial discomfort reported by some patients.
• Elevated liver enzymes: mild increase in hepatic transaminases observed in laboratory tests.
• Phlebitis at infusion site: local vein irritation or redness during IV administration.

Serious or Rare Side Effects

• Seizures: risk increased in patients with renal dysfunction or high plasma concentrations.
• Severe allergic reactions: anaphylaxis, urticaria, or angioedema requiring immediate medical attention.
• Clostridioides difficile colitis: antibiotic‑associated severe diarrhea with potential colonic inflammation.
• Renal dysfunction: acute kidney injury manifesting as rising creatinine levels.
• Hemolytic anemia: rare immune‑mediated destruction of red blood cells.

When using Merocarb, clinicians should observe specific precautions to ensure safety and efficacy.

• Renal function assessment: adjust dosage in patients with impaired renal clearance.
• Monitor for neurotoxicity: observe for seizures or altered mental status, especially in renal failure.
• Allergic history review: avoid use in patients with known hypersensitivity to carbapenems or β‑lactams.
• Concomitant nephrotoxic drugs: use caution when combined with other agents that may affect kidney function.
• Therapeutic drug monitoring: consider plasma level checks in critically ill patients to optimize exposure.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Merocarb can interact with other medicines, affecting its efficacy or increasing toxicity.

Major Interactions (Avoid)

• Valproic acid: may reduce valproate levels, risking loss of seizure control.
• Probenecid: can decrease renal clearance of meropenem, leading to higher plasma concentrations.
• Aminoglycosides: combined nephrotoxicity risk; avoid concurrent high‑dose therapy.

Moderate Interactions (Monitor Closely)

• Loop diuretics: may enhance renal toxicity; monitor renal function.
• Anticoagulants (warfarin): possible alteration of INR; check coagulation parameters.
• Other β‑lactam antibiotics: additive toxicity; assess for overlapping adverse effects.